|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010.
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010.
|
|
3
|
Ross RW, Oh WK, Xie W, et al: Inherited
variation in the androgen pathway is associated with the efficacy
of androgen-deprivation therapy in men with prostate cancer. J Clin
Oncol. 26:842–847. 2008.
|
|
4
|
Debes JD and Tindall DJ: Mechanisms of
androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490.
2004.
|
|
5
|
Chen CD, Welsbie DS, Tran C, et al:
Molecular determinants of resistance to antiandrogen therapy. Nat
Med. 10:33–39. 2004.
|
|
6
|
Choueiri TK, Xie W, D’Amico AV, et al:
Time to prostate-specific antigen nadir independently predicts
overall survival in patients who have metastatic hormone-sensitive
prostate cancer treated with androgen-deprivation therapy. Cancer.
115:981–987. 2009.
|
|
7
|
Bickers B and Aukim-Hastie C: New
molecular biomarkers for the prognosis and management of prostate
cancer - the post PSA era. Anticancer Res. 29:3289–3298. 2009.
|
|
8
|
Shariat SF, Karam JA and Roehrborn CG:
Blood biomarkers for prostate cancer detection and prognosis.
Future Oncol. 3:449–461. 2007.
|
|
9
|
Aksoy S, Szumlanski CL and Weinshilboum
RM: Human liver nicotinamide N-methyltransferase. cDNA cloning,
expression, and biochemical characterization. J Biol Chem.
269:14835–14840. 1994.
|
|
10
|
Rini J, Szumlanski C, Guerciolini R and
Weinshilboum RM: Human liver nicotinamide N-methyltransferase:
ion-pairing radiochemical assay, biochemical properties and
individual variation. Clin Chim Acta. 186:359–374. 1990.
|
|
11
|
Tomida M, Mikami I, Takeuchi S, Nishimura
H and Akiyama H: Serum levels of nicotinamide N-methyltransferase
in patients with lung cancer. J Cancer Res Clin Oncol.
135:1223–1229. 2009.
|
|
12
|
Roessler M, Rollinger W, Palme S, et al:
Identification of nicotinamide N-methyltransferase as a novel serum
tumor marker for colorectal cancer. Clin Cancer Res. 11:6550–6557.
2005.
|
|
13
|
Sartini D, Pozzi V, Renzi E, et al:
Analysis of tissue and salivary nicotinamide N-methyltransferase in
oral squamous cell carcinoma: basis for the development of a
noninvasive diagnostic test for early-stage disease. Biol Chem.
393:505–511. 2012.
|
|
14
|
Sartini D, Muzzonigro G, Milanese G, et
al: Upregulation of tissue and urinary nicotinamide
N-methyltransferase in bladder cancer: potential for the
development of a urine-based diagnostic test. Cell Biochem Biophys.
65:473–483. 2013.
|
|
15
|
Allred DC, Clark GM, Elledge R, et al:
Association of p53 protein expression with tumor cell proliferation
rate and clinical outcome in node-negative breast cancer. J Natl
Cancer Inst. 85:200–206. 1993.
|
|
16
|
Markert JM, Fuller CM, Gillespie GY, et
al: Differential gene expression profiling in human brain tumors.
Physiol Genomics. 5:21–33. 2001.
|
|
17
|
Jang JS, Cho HY, Lee YJ, Ha WS and Kim HW:
The differential proteome profile of stomach cancer: identification
of the biomarker candidates. Oncol Res. 14:491–499. 2004.
|
|
18
|
Xu J, Moatamed F, Caldwell JS, et al:
Enhanced expression of nicotinamide N-methyltransferase in human
papillary thyroid carcinoma cells. J Clin Endocrinol Metab.
88:4990–4996. 2003.
|
|
19
|
Kim J, Hong SJ, Lim EK, et al: Expression
of nicotinamide N-methyltransferase in hepatocellular carcinoma is
associated with poor prognosis. J Exp Clin Cancer Res.
28:202009.
|
|
20
|
Tang SW, Yang TC, Lin WC, et al:
Nicotinamide N-methyltransferase induces cellular invasion through
activating matrix metalloproteinase-2 expression in clear cell
renal cell carcinoma cells. Carcinogenesis. 32:138–145. 2011.
|
|
21
|
Kim HC, Mofarrahi M, Vassilakopoulos T, et
al: Expression and functional significance of nicotinamide N-methyl
transferase in skeletal muscles of patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med.
181:797–805. 2010.
|
|
22
|
Mateuszuk Ł, Khomich TI, Słomińska E, et
al: Activation of nicotinamide N-methyltrasferase and increased
formation of 1-methylnicotinamide (MNA) in atherosclerosis.
Pharmacol Rep. 61:76–85. 2009.
|
|
23
|
Williams AC and Ramsden DB: Autotoxicity,
methylation and a road to the prevention of Parkinson’s disease. J
Clin Neurosci. 12:6–11. 2005.
|
|
24
|
Sakr WA and Partin AW: Histological
markers of risk and the role of high-grade prostatic
intraepithelial neoplasia. Urology. 57:115–120. 2001.
|
|
25
|
Emanuelli M, Santarelli A, Sartini D, et
al: Nicotinamide N-Methyltransferase upregulation correlates with
tumour differentiation in oral squamous cell carcinoma. Histol
Histopathol. 25:15–20. 2010.
|
|
26
|
Zhang J: Are poly(ADP-ribosyl)ation by
PARP-1 and deacetylation by Sir2 linked? Bioessays. 25:808–814.
2003.
|
|
27
|
Jung-Hynes B, Nihal M, Zhong W and Ahmad
N: Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A
target for prostate cancer management via its inhibition? J Biol
Chem. 284:3823–3832. 2009.
|
|
28
|
Parsons RB, Aravindan S, Kadampeswaran A,
et al: The expression of nicotinamide N-methyltransferase increases
ATP synthesis and protects SH-SY5Y neuroblastoma cells against the
toxicity of Complex I inhibitors. Biochem J. 436:145–155. 2011.
|
|
29
|
Ulanovskaya OA, Zuhl AM and Cravatt BF:
NNMT promotes epigenetic remodeling in cancer by creating a
metabolic methylation sink. Nat Chem Biol. 9:300–306. 2013.
|
